Home > Oncology > ASCO 2019 > Lung Cancer > Early results from TAK-788 in NSCLC with EGFR exon 20 insertions

Early results from TAK-788 in NSCLC with EGFR exon 20 insertions

Presented By
Dr Gregory Riely, Memorial Sloan Kettering Cancer Centre, USA
Conference
ASCO 2019
Medical writer: Muriel Cunningham TAK-788 is an investigational oral EGFR/HER2 inhibitor under development for the treatment of non–small cell lung cancer (NSCLC) with EGFR/HER2 mutations, including patients with NSCLC EGFR exon 20 insertions. A phase I/II open-label study of TAK-788 enrolled patients with advanced, previously treated NSCLC from multiple centres (NCT02716116). In the phase I dose-escalation trial, TAK-788 doses ranged from 5 to 180 mg once a day (QD), with a recommended phase II dose (R2PD) of 160 mg QD. Results as of the data cut off (March 1, 2019) were presented by Gregory Riely, MD, PhD, of Memorial Sloan Kettering Cancer Centre during an Oral Abstract Session on June 3 (Abstract 9007). Safety data were reported for the 137 patients who received any dose of TAK-788 and the subgroup of 72 patients treated with at least one dose of TAK-788 at 160 mg QD. Ninety-five percent of patients at any dose or at the R2PD dose expe...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on